Originally published by our sister publication Infectious Disease Special Edition
By Marie Rosenthal, MS
In a unanimous decision, the FDA’s Vaccines and Related Biological Products Advisory Committee recommended the JN.1 and/or a specific JN.1-lineage strain should be used in the 2025-2026 formula for updated COVID-19 vaccines.
As SARS-CoV-2 circulates, it has been mutating with one strain after another becoming dominant. The delta strain became dominant in India in 2020, but by around